Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1312-1319

  Sirohi, B ^a   Cunningham, David ^a,b   Powles, R ^a   Murphy, F ^a   Arkenau, T ^a   Norman, A ^a   Oates, J ^a   Wotherspoon, A ^a   Horwich, A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Autotransplantation; Hodgkin's lymphoma; Refractory; Relapsed

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BLADDER CARCINOMA; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LEUKAPHERESIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SECOND CANCER; STEM CELL MOBILIZATION; STOMACH CANCER; TONGUE CANCER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 46249110117     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn052     Document Type: Article

References (28)

1. Gribben JG, Linch DC, Singer CR et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-344.
2. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous, bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
3. Chopra R, McMillan AK, Linch DC et al. The place of high-dose DEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patents. Blood 1993; 81: 1137-1145.
4. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065-2071.
5. Strehl J, Mey U, Glasmacher A et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: A meta-analysis. Haematologica 2003; 88: 1304-1315.
6. Hasenclever D, Diehl V, Armitage JO et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
7. O'Brien ME, Milan S, Cunningham D et al. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - a pragmatic prognostic index. Br J Cancer 1996; 73: 1272-1277.
8. Sirohi B, Cunningham D, Norman A et al. Long-term outcome of high-dose chemotherapy and autologous stem cell transplantation in relapsed/ refractory Hodgkin's disease: A cohort of 199 pts from Royal Marsden Hospital. J Clin Oncol 2006; 24: 452s(Abstr).
9. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete estimations. J Am Stat Assoc 1958; 53: 457-481.
12. Stiff PJ, Unger JM, Forman SJ et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9: 529-539.
13. Schmitz N, Haverkamp H, Josting A et al. Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT), J Clin Oncol 2005; 23: 562s(Abstr6508).
14. Sureda A, Constans M, Iriondo A et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625-633.
15. Tarella C, Cuttica A, Vitolo U et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free-survivai in patients treated at first recurrence. Cancer 2003; 97: 2748-2759.
16. Wadehra N, Farag S, Bolwell B et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1343-1349.
17. Czyz J, Dziadziuszko R, Knopinska-Postuszuy W et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: A study of 341 patents. Ann Oncol 2004; 15: 1222-1230.
18. Tarella C, Cuttica A, Vitolo U et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patents with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfoml showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97: 2748-2759.
19. Josting A, Rueffer U, Franklin J et al, Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-1286.
20. Hertzberg MS, Crombie C, Benson W et al. Outpatient fractionated ifostamide, cartioplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006; 17 ((Suppl 4)): Iv25-iv30.
21. Sureda A, Arranz R, Iriondo A et al. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patents from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404.
22. Subira M, Sureda A, Martino R et al. Autologous stem cell transplantation for high-risk Hodgkin 's disease: Improvement over time and impact of conditioning regimen. Haematologica 2000; 85: 167-172.
23. Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909.
24. Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/ or peripheral blood stem cell transplantation for patients with' relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-1390.
25. Bonadonna G, Viviani S, Bonfante V et al. Survival in Hodgkin's disease patients - report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005; 41: 998-1006.
26. Horwich A, Swerdlow AJ. Second primary breast cancer after Hodgkin's disease. Br J Cancer 2004; 90: 294-298.
27. Harrison CN, Gregory W, Hudson GV et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 1999; 81: 476-483.
28. Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006: 266-272.